BSE · 543363
Prevest Denpro Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹19 Cr with net profit ₹6 Cr — a 29.73% net margin, versus 26.71% the period before.
Shareholding
As of 2026-06-30
- Promoter73.6%
- Public24.96%
- FII0.65%
- DII0.79%
1,975 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.77× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #36 of 85 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,30,211 Cr | 61.89 | 13.74 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,03,171 Cr | 68.92 | 9.6 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹99,857 Cr | 106.47 | 6.08 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹67,493 Cr | 63.27 | 6.82 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,295 Cr | 170.91 | 15.76 | 8.48% | 6.54% |
| Global Health Limited | ₹40,288 Cr | 70.38 | 10.17 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹39,027 Cr | 45.28 | 8.6 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,517 Cr | 160.56 | 8.94 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,324 Cr | 57.47 | 12.89 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,505 Cr | 54.7 | 5.64 | 10.37% | 15.77% |
| Prevest Denpro Limited(this company) | ₹456 Cr | 21.01 | 3.66 | 16.42% | 28.92% |
AI analysis
AI-generated · google/gemini-2.5-flashPrevest Denpro Limited is listed with a market capitalization of Rs 468 Cr. The company reported a revenue of Rs 67.09 Cr and a profit margin of 28.53%. Its earnings per share (EPS) stands at Rs 17.07. The 52-week high for the share price was Rs 622.05, and the 52-week low was Rs 318.15.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Promoter holding is high at 73.60% as of June 30, 2026.
- +The profit margin is 28.53% for the reported period.
- +Return on capital employed (ROCE) is 22.12%.
Negatives
- −Revenue growth information is not available in the provided data.
- −No dividend yield has been reported for the company.
- −Quarterly EPS figures are not disclosed since March 2025.
Financial Performance
For the fiscal year ending March 2025, Prevest Denpro Limited reported a revenue of Rs 67.09 Cr and a net profit of Rs 18.15 Cr. The EPS for this period was Rs 15.13. Quarterly results for March 2026 show a revenue of Rs 18.94 Cr and a net profit of Rs 5.82 Cr.
Profitability & Returns
The company recorded a profit margin of 28.53%. Return on equity (ROE) for Prevest Denpro Limited is 16.42%, and return on capital employed (ROCE) is 22.12%. This indicates how efficiently the company is generating profits from its equity and capital.
Balance Sheet
Prevest Denpro Limited has a debt-to-equity ratio of 0, indicating the company operates without debt in its capital structure. The book value per share is Rs 103.98.
Ownership & Pledges
Public shareholding stands at 24.96%. There are no reported pledged promoter shares.
Data as of — price: 2026-09-23 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.